9 research outputs found
The influence of drug interactions on the international Normalized Ratio (INR) in hospitalized patients on warfarin therapy
Interakcije lijekova predstavljaju znaÄajno podruÄje istraživanja u suvremenoj
medicini. Varfarin kao temeljni lijek pri lijeÄenju i prevenciji duboke venske tromboze,
pluÄne embolije i drugih bolesti, zbog svoje specifiÄne graÄe, biotransformacije, metabolizma,
individualnog doziranja i opasnosti od krvarenja predstavlja trajni izazov.
U svrhu pokuÅ”aja evaluacije utjecaja interakcija lijekova na meÄunarodni
normalizirani omjer (INR) kao temeljni parametar praÄenja terapije varfarinom, tijekom ovog
istraživanja je koriÅ”ten raÄunalni program za probir interakcija Lexi-Interact.
U radu je provedena analiza 339 bolesnika kojima je tijekom hospitalizacije
zapoÄeta terapija varfarinom, te su temeljem programa podijeljeni u ispitnu skupinu (223
bolesnika) sa moguÄim kliniÄki znaÄajnim interakcijama s varfarinom i kontrolnu skupinu
(116 bolesnika) bez njih. Bolesnici su u prosjeku istodobno dobivali 5,28 lijekova (od
1-13 lijekova po bolesniku). Analizom rezultata vidljivo je da je 65,8% bolesnika bilo
izloženo kliniÄki znaÄajnim interakcijama (1-6 interakcija po bolesniku). StatistiÄki
znaÄajna razlika izmeÄu navedene dvije skupine zabilježena je samo u broju lijekova,
izuzev varfarina, kojima su bolesnici bili lijeÄeni. Interakcije nisu statistiÄki znaÄajno
utjecale na vrijednosti INR-a sedmog dana terapije, kao ni na visinu doze varfarina istog
dana. ZnaÄajan utjecaj interakcija nije zabilježen pri podjeli bolesnika na podskupine s
ciljnim INR izmeÄu 2 i 3, te one iznad i ispod tih vrijednosti, kao niti na uÄestalost
zabilježenih nuspojava.
ZakljuÄno, ovim istraživanjem nije dokazan utjecaj interakcija varfarina s drugim
lijekovima na meÄunarodni normalizirani omjer, te individualno titriranje i praÄenje
ostaje temelj njegova uvoÄenja u terapiju.Drug interactions represent an important area of research in modern medicine.
Warfarin, as the basic drug for treatment and prevention of deep venous thrombosis,
pulmonary embolism and other diseases, due to its specific composition, biotransformation,
metabolism, individual dosing and the risk of bleeding represents a permanent challenge.
In the attempt to evaluate the influence of drug interactions on the International
Normalized Ratio (INR), the computer program for screening drug interactions called Lexi-
Interact was used during this research as the basic parameter for monitoring warfarin
therapy.
In this paper, the analysis of 339 patients whose warfarin therapy began during
hospitalization was conducted. Based on the program, they were divided into the group
with (223 patients), and the group without (116 patients) possible clinically significant
interactions. On the average, the patients were concurrently taking 5.28 drugs (1-13 drugs per
patient). The analysis of results shows that 65.8% of patients were exposed to clinically
significant interactions (1-6 interactions per patient). Statistically significant difference
between the two groups was recorded only in the number of drugs, apart from warfarin,
the patients were treated with. The interactions did not have a statistically significant
impact on the INR values on the day 7 of therapy or on the dose of warfarin on the same day.
A significant influence of interactions was not recorded in the division of patients into
subgroups with target INR between 2 and 3, and those above and under those values; or
on the frequency of recorded side-effects.
In conclusion, this research did not prove the influence of warfarin interactions with
other drugs on the International Normalized Ratio, and therefore individual titration and
monitoring remains the basis of its introduction into therapy
The Relationship between Methylenetetrahydro-folate Reductase C677T Gene Polymorphism and Diabetic Nephropathy in Croatian Type 2 Diabetic Patients
Methylenetetrahydrofolate reductase (MTHFR) polymorphism has been shown to be associated with the development of diabetic nephropathy in many ethnic groups. In this study, we examined the correlation between MTHFR C677T poly- morphism and microalbuminuria in patients with diabetes mellitus type 2 in Croatian patients. 85 patients with diabetes mellitus type 2 were recruited. Patients were classified into two groups ā with and without diabetic nephropathy ac- cording to urinary albumin excretion rate in urine collected during 24 hours. The C677T genotype was determined by real-time PCR analysis. The genotype frequencies were CC 36,5%, CT 42,3% and TT 21,2% in diabetic patients without nephropathy versus CC 39,4%, CT 45,4% and TT 15,2% in those with nephropathy. There was no statistically significant difference in allele distribution between patients with nephropathy and those without (p=0,788). Our study did not show a correlation between mutations in the MTHFR gene and diabetic nephropathy in Croatian patients. Diabetic nephropathy is influenced by multiple risk factors which can modify the importance of MTHFR polymorphism in its de- velopment
Hrvatske smjernice za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2 [Croatian guidelines for the pharmacotherapy of type 2 diabetes]
Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the pharmacotherapy of type 2 diabetes in the Republic of Croatia.
Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetes' patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglyce- mia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes
CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES
Uvod: Hrvatsko druÅ”tvo za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora izradilo je 2011. godine prve nacionalne smjernice o prehrani, edukaciji i samokontroli te farmakoloÅ”kom lijeÄenju Å”eÄerne bolesti tipa 2. Sukladno poveÄanom broju dostupnih lijekova te novim spoznajama o uÄinkovitosti i sigurnosti primjene veÄ ukljuÄenih lijekova, pokazala se potreba za obnovom postojeÄih smjernica za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2 u Republici ĀHrvatskoj. Sudionici: Kao koautori Smjernica navedeni su svi Älanovi Hrvatskog druÅ”tva za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora, kao i ostalih ukljuÄenih struÄnih druÅ”tava, koji su svojim komentarima i prijedlozima pridonijeli izradi Smjernica. Dokazi: Ove su Smjernice utemeljene na dokazima, prema sustavu GRADE (engl. Grading of Recommendations, Assessment, Development and Evaluation) koji uz razinu dokaza opisuje i snagu preporuke. ZakljuÄci: Individualan pristup temeljen na fizioloÅ”kim principima regulacije glikemije nuždan je u lijeÄenju osoba sa Å”eÄernom bolesti. Ciljeve lijeÄenja i odabir medikamentne terapije treba prilagoditi oboljeloj osobi, uzimajuÄi u obzir životnu dob, trajanje bolesti, oÄekivano trajanje života, rizik od hipoglikemije, komorbiditete, razvijene vaskularne i ostale komplikacije, kao i ostale Äimbenike. Zbog svega navedenoga od nacionalnog je interesa imati praktiÄne, racionalne i provedive smjernice za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2.Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of Ādiabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the Āpharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetesā patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglycemia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes
The relationship between methylenetetrahydrofolate reductase C677T gene polymorphism and diabetic nephropathy in Croatian type 2 diabetic patients [Povezanost polimirfizma C677T gena za metilentetrahidrofolat reduktazu i dijabetiÄke nefropatije u bolesnika sa Å”eÄernom bolesti tip 2 u Hrvatskoj]
Methylenetetrahydrofolate reductase (MTHFR) polymorphism has been shown to be associated with the development of diabetic nephropathy in many ethnic groups. In this study, we examined the correlation between MTHFR C677T polymorphism and microalbuminuria in patients with diabetes mellitus type 2 in Croatian patients. 85 patients with diabetes mellitus type 2 were recruited. Patients were classified into two groups--with and without diabetic nephropathy according to urinary albumin excretion rate in urine collected during 24 hours. The C677T genotype was determined by real-time PCR analysis. The genotype frequencies were CC 36.5%, CT 42.3% and TT 21.2% in diabetic patients without nephropathy versus CC 39.4%, CT 45.4% and TT 15.2% in those with nephropathy. There was no statistically significant difference in allele distribution between patients with nephropathy and those without (p = 0.788). Our study did not show a correlation between mutations in the MTHFR gene and diabetic nephropathy in Croatian patients. Diabetic nephropathy is influenced by multiple risk factors which can modify the importance of MTHFR polymorphism in its development
Povezanost polimirfizma C677T gena za metilentetrahidrofolat reduktazu i dijabetiÄke nefropatije u bolesnika sa Å”eÄernom bolesti tip 2 u Hrvatskoj
Methylenetetrahydrofolate reductase (MTHFR) polymorphism has been shown to be associated with the development of diabetic nephropathy in many ethnic groups. In this study, we examined the correlation between MTHFR C677T polymorphism and microalbuminuria in patients with diabetes mellitus type 2 in Croatian patients. 85 patients with diabetes mellitus type 2 were recruited. Patients were classified into two groups--with and without diabetic nephropathy according to urinary albumin excretion rate in urine collected during 24 hours. The C677T genotype was determined by real-time PCR analysis. The genotype frequencies were CC 36.5%, CT 42.3% and TT 21.2% in diabetic patients without nephropathy versus CC 39.4%, CT 45.4% and TT 15.2% in those with nephropathy. There was no statistically significant difference in allele distribution between patients with nephropathy and those without (p = 0.788). Our study did not show a correlation between mutations in the MTHFR gene and diabetic nephropathy in Croatian patients. Diabetic nephropathy is influenced by multiple risk factors which can modify the importance of MTHFR polymorphism in its development.Polimorfizam gena za metilentetrahidrofolat reduktazu (MTHFR) je povezan s razvojem dijabetiÄke nefropatije u
mnogim etniÄkim skupinama.U ovoj studiji istraživali smo povezanost izmeÄu polimorfizma C677T gena za MTHFR i
mikroalbuminurije u bolesnika sa Å”eÄernom bolesti tip 2 u hrvatskih bolesnika. Osamdeset pet bolesnika sa Å”eÄernom
bolesti je obraÄivano i svrstano u dvije skupine ā sa dijabetiÄkom nefropatijom i bez nje, ovisno o vrijednostima izluÄenog
albumina u 24-satnom urinu. Mutacija C677T gena za MTHFR odreÄena je metodom izolacije DNA i alel specifiÄne
lanÄane reakcije polimeraze (PCR). Raspodjela genotipova u skupini bolesnika s normoalbuminurijom bila je: CC
36,5%, CT 42,3% i TT 21,2%, dok je u skupini bolesnika sa mikroalbuminurijom bila: CC 39,4%, CT 45,4% i TT 15,2%.
Nije bilo statistiÄki znaÄajne razlike meÄu grupama u distribuciji C677T genotipova (p=0,788). NaÅ”e istraživanje nije
pokazalo povezanost izmeÄu mutacije gena za metilentetrahidrofolat reduktazu i dijabetiÄke nefropatije u hrvatskih
bolesnika. Mnogostruki Äimbenici mogu modificirati znaÄajnost utjecaja polimorfizma MTHFR na nastanak dijabetiÄke
nefropatije
Povezanost polimirfizma C677T gena za metilentetrahidrofolat reduktazu i dijabetiÄke nefropatije u bolesnika sa Å”eÄernom bolesti tip 2 u Hrvatskoj
Methylenetetrahydrofolate reductase (MTHFR) polymorphism has been shown to be associated with the development of diabetic nephropathy in many ethnic groups. In this study, we examined the correlation between MTHFR C677T polymorphism and microalbuminuria in patients with diabetes mellitus type 2 in Croatian patients. 85 patients with diabetes mellitus type 2 were recruited. Patients were classified into two groups--with and without diabetic nephropathy according to urinary albumin excretion rate in urine collected during 24 hours. The C677T genotype was determined by real-time PCR analysis. The genotype frequencies were CC 36.5%, CT 42.3% and TT 21.2% in diabetic patients without nephropathy versus CC 39.4%, CT 45.4% and TT 15.2% in those with nephropathy. There was no statistically significant difference in allele distribution between patients with nephropathy and those without (p = 0.788). Our study did not show a correlation between mutations in the MTHFR gene and diabetic nephropathy in Croatian patients. Diabetic nephropathy is influenced by multiple risk factors which can modify the importance of MTHFR polymorphism in its development.Polimorfizam gena za metilentetrahidrofolat reduktazu (MTHFR) je povezan s razvojem dijabetiÄke nefropatije u
mnogim etniÄkim skupinama.U ovoj studiji istraživali smo povezanost izmeÄu polimorfizma C677T gena za MTHFR i
mikroalbuminurije u bolesnika sa Å”eÄernom bolesti tip 2 u hrvatskih bolesnika. Osamdeset pet bolesnika sa Å”eÄernom
bolesti je obraÄivano i svrstano u dvije skupine ā sa dijabetiÄkom nefropatijom i bez nje, ovisno o vrijednostima izluÄenog
albumina u 24-satnom urinu. Mutacija C677T gena za MTHFR odreÄena je metodom izolacije DNA i alel specifiÄne
lanÄane reakcije polimeraze (PCR). Raspodjela genotipova u skupini bolesnika s normoalbuminurijom bila je: CC
36,5%, CT 42,3% i TT 21,2%, dok je u skupini bolesnika sa mikroalbuminurijom bila: CC 39,4%, CT 45,4% i TT 15,2%.
Nije bilo statistiÄki znaÄajne razlike meÄu grupama u distribuciji C677T genotipova (p=0,788). NaÅ”e istraživanje nije
pokazalo povezanost izmeÄu mutacije gena za metilentetrahidrofolat reduktazu i dijabetiÄke nefropatije u hrvatskih
bolesnika. Mnogostruki Äimbenici mogu modificirati znaÄajnost utjecaja polimorfizma MTHFR na nastanak dijabetiÄke
nefropatije
CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES
Uvod: Hrvatsko druÅ”tvo za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora izradilo je 2011. godine prve nacionalne smjernice o prehrani, edukaciji i samokontroli te farmakoloÅ”kom lijeÄenju Å”eÄerne bolesti tipa 2. Sukladno poveÄanom broju dostupnih lijekova te novim spoznajama o uÄinkovitosti i sigurnosti primjene veÄ ukljuÄenih lijekova, pokazala se potreba za obnovom postojeÄih smjernica za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2 u Republici ĀHrvatskoj. Sudionici: Kao koautori Smjernica navedeni su svi Älanovi Hrvatskog druÅ”tva za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora, kao i ostalih ukljuÄenih struÄnih druÅ”tava, koji su svojim komentarima i prijedlozima pridonijeli izradi Smjernica. Dokazi: Ove su Smjernice utemeljene na dokazima, prema sustavu GRADE (engl. Grading of Recommendations, Assessment, Development and Evaluation) koji uz razinu dokaza opisuje i snagu preporuke. ZakljuÄci: Individualan pristup temeljen na fizioloÅ”kim principima regulacije glikemije nuždan je u lijeÄenju osoba sa Å”eÄernom bolesti. Ciljeve lijeÄenja i odabir medikamentne terapije treba prilagoditi oboljeloj osobi, uzimajuÄi u obzir životnu dob, trajanje bolesti, oÄekivano trajanje života, rizik od hipoglikemije, komorbiditete, razvijene vaskularne i ostale komplikacije, kao i ostale Äimbenike. Zbog svega navedenoga od nacionalnog je interesa imati praktiÄne, racionalne i provedive smjernice za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2.Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of Ādiabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the Āpharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetesā patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglycemia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes
CROATIAN GUIDELINES FOR THE PHARMACOTHERAPY OF TYPE 2 DIABETES
Uvod: Hrvatsko druÅ”tvo za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora izradilo je 2011. godine prve nacionalne smjernice o prehrani, edukaciji i samokontroli te farmakoloÅ”kom lijeÄenju Å”eÄerne bolesti tipa 2. Sukladno poveÄanom broju dostupnih lijekova te novim spoznajama o uÄinkovitosti i sigurnosti primjene veÄ ukljuÄenih lijekova, pokazala se potreba za obnovom postojeÄih smjernica za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2 u Republici ĀHrvatskoj. Sudionici: Kao koautori Smjernica navedeni su svi Älanovi Hrvatskog druÅ”tva za dijabetes i bolesti metabolizma Hrvatskoga lijeÄniÄkog zbora, kao i ostalih ukljuÄenih struÄnih druÅ”tava, koji su svojim komentarima i prijedlozima pridonijeli izradi Smjernica. Dokazi: Ove su Smjernice utemeljene na dokazima, prema sustavu GRADE (engl. Grading of Recommendations, Assessment, Development and Evaluation) koji uz razinu dokaza opisuje i snagu preporuke. ZakljuÄci: Individualan pristup temeljen na fizioloÅ”kim principima regulacije glikemije nuždan je u lijeÄenju osoba sa Å”eÄernom bolesti. Ciljeve lijeÄenja i odabir medikamentne terapije treba prilagoditi oboljeloj osobi, uzimajuÄi u obzir životnu dob, trajanje bolesti, oÄekivano trajanje života, rizik od hipoglikemije, komorbiditete, razvijene vaskularne i ostale komplikacije, kao i ostale Äimbenike. Zbog svega navedenoga od nacionalnog je interesa imati praktiÄne, racionalne i provedive smjernice za farmakoloÅ”ko lijeÄenje Å”eÄerne bolesti tipa 2.Introduction: The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of Ādiabetes type 2. According to the increased number of available medicines and new evidence related to the effectiveness and safety of medicines already involved in the therapy there was a need for update of the existing guidelines for the Āpharmacotherapy of type 2 diabetes in the Republic of Croatia. Participants: as co-authors of the Guidelines there are listed all members of the Croatian Association for Diabetes and Metabolic Diseases, as well as other representatives of professional societies within the Croatian Medical Association, who have contributed with comments and suggestions to the development of the Guidelines. Evidence: These guidelines are evidence-based, according to the GRADE system (eng. Grading of Recommendations, Assessment, Development and Evaluation), which describes the level of evidence and strength of recommendations. Conclusions: An individual patient approach based on physiological principles in blood glucose control is essential for diabetesā patients management. Glycemic targets and selection of the pharmacological agents should be tailored to the patient, taking into account the age, duration of disease, life expectancy, risk of hypoglycemia, comorbidities, developed vascular and other complications as well as other factors. Because of all this, is of national interest to have a practical, rational and applicable guidelines for the pharmacotherapy of type 2 diabetes